| Recruiting | AI-Powered Precision Decision-Making for Pancreatic Diseases NCT07439757 | Changhai Hospital | — |
| Recruiting | Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy NCT07328607 | Minia University | N/A |
| Recruiting | Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not NCT07273409 | Uppsala University | N/A |
| Recruiting | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metast NCT04119024 | Anusha Kalbasi | Phase 1 |
| Active Not Recruiting | ATRX/DAXX in EUS-FNB Specimens of Pan-NETs NCT06406387 | Azienda Ospedaliera Universitaria Integrata Verona | — |
| Recruiting | Multicenter Trial of ESK981 in Patients With Select Solid Tumors NCT05988918 | University of Michigan Rogel Cancer Center | Phase 2 |
| Recruiting | Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours NCT06121622 | IRCCS San Raffaele | — |
| Recruiting | Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) NCT06141369 | Shanghai Jiao Tong University School of Medicine | N/A |
| Not Yet Recruiting | Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy NCT06167421 | Fudan University | N/A |
| Not Yet Recruiting | A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors NCT06158516 | Changhai Hospital | Phase 2 |
| Recruiting | Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestin NCT05997056 | Aadi Bioscience, Inc. | Phase 2 |
| Recruiting | Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations NCT06041009 | Qilu Hospital of Shandong University | — |
| Withdrawn | Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver NCT05610826 | University of Chicago | Phase 1 / Phase 2 |
| Recruiting | Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors NCT05847855 | Fudan University | — |
| Completed | Artificial Intelligence in EUS for Diagnosing Pancreatic Solid Lesions NCT05476978 | Huazhong University of Science and Technology | — |
| Recruiting | Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors NCT05040360 | SWOG Cancer Research Network | Phase 2 |
| Completed | Study on Microflora Characteristics of Pancreatic Solid Lesions Via Endoscopic Ultrasound-guided Fine Needle A NCT05171517 | Peking Union Medical College Hospital | — |
| Recruiting | Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocr NCT04924075 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced NCT04505553 | University of Washington | Phase 2 |
| Terminated | Neoadjuvant PRRT With Y-90-DOTATOC in pNET NCT05568017 | European Institute of Oncology | Phase 2 |
| Active Not Recruiting | Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine T NCT03891784 | University of Washington | Phase 2 |
| Terminated | Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical NCT03947762 | Ipsen | — |
| Completed | Pancreatic Fistula After Minimally Invasive Enucleation NCT06557408 | Fudan University | — |
| Completed | Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or Reconstruction NCT06024343 | Fudan University | N/A |
| Unknown | Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region NCT04134832 | University Hospital, Strasbourg, France | — |
| Completed | CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms NCT03967951 | Francesco De Cobelli | — |
| Unknown | Biomarker Study of Pancreatic Neuroendocrine Tumours NCT03741517 | Uppsala University | — |
| Active Not Recruiting | Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors NCT03600233 | TaiRx, Inc. | Phase 2 |
| Completed | A Bioequivalence Study of Sunitinib Malate Capsules. NCT05800106 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Unknown | EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors NCT05566093 | Guangxi Medical University | N/A |
| Unknown | Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms NCT03435770 | Singapore General Hospital | N/A |
| Unknown | Safety and Efficacy of an Ablation Catheter for the Treatment of Pancreatic Premalignant Cyctic Lesions. NCT03417843 | HaEmek Medical Center, Israel | N/A |
| Completed | Laser Tissue Welding - Distal Pancreatectomy Sealing Study NCT03147768 | Laser Tissue Welding, Inc. | Phase 1 |
| Active Not Recruiting | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors NCT03074513 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Sub NCT03204019 | Chinese Academy of Medical Sciences | Phase 2 |
| Unknown | Pancreatic Neuroendocrine Tumor：Factor of Surgery Influencing Survival NCT02624154 | First Affiliated Hospital, Sun Yat-Sen University | — |
| Unknown | EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors NCT05554744 | Guangxi Medical University | N/A |
| Completed | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 NCT02355535 | Vanquish Oncology, Inc. | Phase 1 |
| Completed | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Canno NCT02159989 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors NCT01466036 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors NCT01024387 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease NCT00970970 | University Medical Center Groningen | — |
| Completed | Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors NCT00942682 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors NCT00804336 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors NCT00576680 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Completed | A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. NCT00428220 | Pfizer | N/A |